RYAN DUARTE: Open Payments
NPI 1720127020 · PASCO, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,171 in 93 payments from 16 companies in 2025. Trend: 2023 $2,552 · 2024 $2,536 · 2025 $2,171
Food & beverage: $2,162Education: $10
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $366 |
| UCB, Inc. | 16 | $339 |
| Galderma Laboratories, L.P. | 10 | $287 |
| Janssen Biotech, Inc. | 12 | $245 |
| Lilly USA, LLC | 9 | $207 |
| GENZYME CORPORATION | 2 | $144 |
| Blueprint Medicines Corporation | 1 | $118 |
| Incyte Corporation | 1 | $115 |
| E.R. Squibb & Sons, L.L.C. | 5 | $97 |
| Regeneron Healthcare Solutions, Inc. | 3 | $78 |
Products named: Bimzelx, TREMFYA, NEMLUVIO, SKYRIZI, DUPIXENT, RINVOQ, TALTZ, AYVAKIT.
Industry payments across WA — which companies pay providers there.
